Skip to search formSkip to main contentSkip to account menu

LX1031

Known as: LX 1031, LX-1031 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.
  • M. Camilleri
  • IDrugs : the investigational drugs journal
  • 2010
  • Corpus ID: 39802235
LX-1031, being developed by Lexicon Pharmaceuticals, is an oral, small-molecule tryptophan 5-hydroxylase (TPH) inhibitor that… 
2010
2010
S1053 Serotonin Biomarker Levels Correlate With Clinical Response in Phase 2 Trial of LX1031, a Novel Serotonin Synthesis Inhibitor for Non-Constipating IBS
2010
2010
907 LX1031, a Novel Locally-Acting Inhibitor of Serotonin (5-HT) Synthesis Significantly Improves Symptoms in Patients With IBS
2010
2010
Serotonin synthesis inhibitors: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome.
e13543 Background: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and… 
2009
2009
237 LX1031: A New Approach for Managing Irritable Bowel Syndrome (IBS)
2007
2007
From Mouse Knockout to Investigational Drug: LX1031, a Novel Potential Treatment for Irritable Bowel Syndrome: 1055
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)